Alpha Diallo
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Furiex Pharmaceuticals Up above 100%

 (Image source:

Furiex Pharmaceuticals Inc (NASDAQ:FURX) are soaring in early trading as a result of two phase three clinical trials for its drug Eluxadoline clearing FDA and European Medicines Agency standards. Eluxadoline is used in the treatment of diarrhea-predominant irritable bowel syndrome. About 28 million people in the U.S. and Europe suffer from irritable bowel syndrome from diarrhea. The company is forecasting sales in the range of $750 million to $1 billion from the drug.